Table 3

Medications and outcomes of patients during 77 pregnancies, stratified based on APS history (outcomes were TLD with no pregnancy morbidity unless indicated otherwise)

TreatmentHistory of OAPS
(N:9)
History of TAPS
(N:25)
History of OAPS+TAPS
(N:24)
No TAPS/OAPS
(N:19)
# of patientsPregnancy
morbidity
# of patientsPregnancy
morbidity
# of patientsPregnancy
morbidity
# of patientsPregnancy
morbidity
LDA2FD:1
EPL:1
14PTLD:1
FD:1
EPL:1
Prophylactic dose LMWH11
Therapeutic dose LMWH2FD:111
LDA+prophylactic dose LMWH4PTLD+SGA:1
EPL:1
23TLD+PEC:1
EPL:1
5TLD+SGA:1
LDA+therapeutic dose LWMH316PTLD:1
PTLD+SGA:1
PTLD+PEC:2
EPL:5
FD:2*
16TLD+SGA+PEC:1
PTLD:2
PTLD+PEC:1
EPL:4
FD:1
4PTLD:1
PTLD+PEC:2
FD:1*
LDA+prophylactic dose UFH1EPL:1
No treatment4EPL:33FD:1
EPL:2
3FD:1
EPL:1
  • In 22/67 pregnancies, LDA and/or LMWH started preconceptionally, in 45/67 pregnancies LDA and/or LMWH started after the conception (mean and median gestational weeks of treatment initiation are 4.6 weeks and 5 weeks, respectively).

  • *Fetal death associated with anomalies (triple X syndrome and cystic fibrosis, respectively).

  • APS, antiphospholipid syndrome; EPL, early pregnancy loss; FD, fetal death; LDA, low-dose aspirin; LMWH, low-molecular-weight heparin; OAPS, obstetric APS; PEC, pre-eclampsia; PTLD, preterm live delivery; SGA, small-for-gestational age; TAPS, thrombotic APS; TLD, term live delivery; UFH, unfractionated heparin.